These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 2163805)

  • 1. Effects of alpha-glucosidase inhibition and viscous fibre on diabetic control and postprandial gut hormone responses.
    Requejo F; Uttenthal LO; Bloom SR
    Diabet Med; 1990 Jul; 7(6):515-20. PubMed ID: 2163805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does suppression of postprandial blood glucose excursions by the alpha-glucosidase inhibitor miglitol improve insulin sensitivity in diet-treated type II diabetic patients?
    Johnson AB; Taylor R
    Diabetes Care; 1996 Jun; 19(6):559-63. PubMed ID: 8725851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Placebo-controlled trial of the effects of guar gum and metformin on fasting blood glucose and serum lipids in obese, type 2 diabetic patients.
    Lalor BC; Bhatnagar D; Winocour PH; Ishola M; Arrol S; Brading M; Durrington PN
    Diabet Med; 1990; 7(3):242-5. PubMed ID: 2158410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the alpha-glucosidase inhibitor 1 desoxynojirimycin (Bay m 1099) on postprandial blood glucose, serum insulin and C-peptide levels in type II diabetic patients.
    Schnack C; Röggla G; Luger A; Schernthaner G
    Eur J Clin Pharmacol; 1986; 30(4):417-9. PubMed ID: 3527720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-prandial glycaemic reduction by an alpha-glucosidase inhibitor in type 2 diabetic patients with therapeutically attained basal normoglycaemia.
    Holman RR; Steemson J; Turner RC
    Diabetes Res; 1991 Dec; 18(4):149-53. PubMed ID: 1842749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effectiveness of a new alpha-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated type 2 diabetes mellitus.
    Mitrakou A; Tountas N; Raptis AE; Bauer RJ; Schulz H; Raptis SA
    Diabet Med; 1998 Aug; 15(8):657-60. PubMed ID: 9702468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of BAYm 1099, new alpha-glucosidase inhibitor, on acute metabolic responses and metabolic control in NIDDM over 1 mo.
    Samad AH; Ty Willing TS; Alberti KG; Taylor R
    Diabetes Care; 1988 Apr; 11(4):337-44. PubMed ID: 3042310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Miglitol (Bay m1099), a new alpha-glucosidase inhibitor, on glucose, insulin, C-peptide and GIP responses to an oral sucrose load in patients with post-prandial hypoglycaemic symptoms.
    Renard E; Parer-Richard C; Richard JL; Jureidini S; Orsetti A; Mirouze J
    Diabete Metab; 1991; 17(3):355-62. PubMed ID: 1884880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of low dose guar in non-insulin dependent diabetic patients.
    Lim HS; Ee CH; Aw TC
    Ann Acad Med Singap; 1990 Jul; 19(4):455-8. PubMed ID: 2221802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of guar gum, wheat bran and placebo on carbohydrate and lipid metabolism in type II diabetics].
    Stahl M; Berger W
    Schweiz Med Wochenschr; 1990 Mar; 120(12):402-8. PubMed ID: 2157279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of postprandial blood glucose by the alpha-glucosidase inhibitor Miglitol (BAY m 1099) in type II diabetes.
    Heinz G; Komjati M; Korn A; Waldhäusl W
    Eur J Clin Pharmacol; 1989; 37(1):33-6. PubMed ID: 2687007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha glucosidase inhibition in the treatment of non-insulin-dependent diabetes mellitus.
    Scott AR; Tattersall RB
    Diabet Med; 1988 Jan; 5(1):42-6. PubMed ID: 2964327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic consequences of the alpha-glucosidase inhibitor BAY-M-1099 given to nondiabetic and diabetic rats fed a high-carbohydrate diet.
    Madar Z
    Am J Clin Nutr; 1989 Jan; 49(1):106-11. PubMed ID: 2643291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new alpha-glucosidase inhibitor (Bay-m-1099) reduces insulin requirements with meals in insulin-dependent diabetes mellitus.
    Kennedy FP; Gerich JE
    Clin Pharmacol Ther; 1987 Oct; 42(4):455-8. PubMed ID: 3311550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long term effects of guar gum on metabolic control, serum cholesterol and blood pressure levels in type 2 (non-insulin-dependent) diabetic patients with high blood pressure.
    Uusitupa M; Tuomilehto J; Karttunen P; Wolf E
    Ann Clin Res; 1984; 16 Suppl 43():126-31. PubMed ID: 6398982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of 8-wk alpha-glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled type II diabetic patients.
    Schnack C; Prager RJ; Winkler J; Klauser RM; Schneider BG; Schernthaner G
    Diabetes Care; 1989 Sep; 12(8):537-43. PubMed ID: 2673693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of alpha-glucosidase inhibition on glucose profiles in insulin dependent diabetes.
    Hillman RJ; Scott M; Gray RS
    Diabetes Res; 1989 Feb; 10(2):81-4. PubMed ID: 2663321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased urinary glucose excretion and plasma cholesterol level in non-insulin dependent diabetic patients with guar.
    Johansen K
    Diabete Metab; 1981 Jun; 7(2):87-90. PubMed ID: 6265299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guar sprinkled on food: effect on glycaemic control, plasma lipids and gut hormones in non-insulin dependent diabetic patients.
    Fuessl HS; Williams G; Adrian TE; Bloom SR
    Diabet Med; 1987; 4(5):463-8. PubMed ID: 2959439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flattening postprandial blood glucose responses with guar gum: acute effects.
    McIvor ME; Cummings CC; Leo TA; Mendeloff AI
    Diabetes Care; 1985; 8(3):274-8. PubMed ID: 2988887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.